FDA Warns Novo Nordisk Over Ozempic & Wegovy Safety Reporting Issues

Federal regulators have issued a warning to Novo Nordisk, the manufacturer of the widely used medications Ozempic and Wegovy, citing failures in its reporting of potential drug side effects. The U.S. Food and Drug Administration (FDA) outlined “serious violations” in a March 5 warning letter, specifically concerning the timely reporting of adverse events, including three patient deaths.

The FDA’s concerns center on how quickly Novo Nordisk shared safety information with the agency, rather than suggesting the medications themselves caused the reported events. This case underscores the critical importance of robust safety reporting systems for pharmaceutical companies and the FDA’s role in monitoring drug safety post-approval.

What the FDA Found

During a routine inspection of Novo Nordisk’s New Jersey facility in early 2025, FDA investigators identified issues with the company’s compliance with Postmarketing Adverse Drug Experience (PADE) reporting regulations. PADE reports are essential safety updates that drug manufacturers are legally required to submit to the FDA after a medication has been approved for public use. The inspection revealed that Novo Nordisk failed to report several serious adverse events within the required timeframe.

Among the unreported events were three deaths of patients taking semaglutide – the active ingredient in both Ozempic and Wegovy. Disturbingly, one of these deaths involved a patient who died by suicide, and another case involved a patient reporting suicidal ideation. The FDA emphasized that the warning letter does not establish a causal link between the medications and these deaths, but rather focuses on the procedural failure to report them promptly.

Semaglutide and its Uses

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, initially developed to manage type 2 diabetes. Semaglutide works by mimicking the effects of a natural hormone that helps regulate blood sugar levels. Still, it has similarly gained significant popularity as a weight-loss medication, particularly Wegovy, which is specifically approved for chronic weight management. The increasing demand for these drugs has also led to concerns about counterfeit products, as noted in a previous report.

What Which means for Patients

The FDA’s warning doesn’t indicate an immediate safety risk requiring patients to stop taking Ozempic or Wegovy. However, it does highlight the importance of ongoing vigilance and transparent communication between pharmaceutical companies and regulatory agencies. The agency relies on timely and accurate PADE reports to continuously monitor the safety profile of drugs and identify potential risks.

Patients taking Ozempic or Wegovy who experience any concerning side effects should promptly report them to their healthcare provider. It’s also crucial to obtain medications from reputable sources to avoid the risk of counterfeit drugs.

Beyond Semaglutide: Emerging Vision Loss Concerns

This warning comes alongside growing scrutiny of GLP-1 drugs like Ozempic and Wegovy regarding potential side effects. Recent research has linked these medications to an increased risk of vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION), sometimes referred to as an “eye stroke.” A study published in the British Journal of Ophthalmology found that individuals using Wegovy had nearly five times the risk of developing NAION compared to those taking Ozempic. Drugwatch reports that people are now filing lawsuits over claims of vision loss after taking these drugs. The European Medicines Agency also determined in 2025 that NAION was a potential side effect of Ozempic and Wegovy.

Novo Nordisk’s Response

Novo Nordisk acknowledged the FDA’s warning letter and stated This proves “working diligently” to address the concerns raised. Anna Windle, head of clinical development, medical and regulatory affairs at the company, said Novo Nordisk takes PADE reporting requirements seriously and plans to address the FDA’s requests “expeditiously and holistically.” The company maintains that the letter does not question the quality or safety of its medications.

The FDA’s Next Steps

The FDA has given Novo Nordisk 15 business days to respond to the warning letter, outlining the specific actions the company will take to prevent similar violations in the future. The agency will then review Novo Nordisk’s response and determine whether further action is necessary. This process may include additional inspections, requests for further information, or potential enforcement actions.

This situation serves as a reminder of the complex interplay between drug innovation, patient safety, and regulatory oversight. The FDA’s ongoing monitoring and enforcement efforts are crucial to ensuring that medications remain safe and effective for those who rely on them.

For more information on PADE reports, visit the FDA website.